Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HF0220 safety, tolerability, and biomarker study in mild to moderate Alzheimer's disease
2005-005791-32Phase 2Completed
- Sponsor
- Hunter-Fleming
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of 7-beta-hydroxyepiandrosterone in Alzheimer's disease (AD), sponsored by Hunter-Fleming. Primary endpoint: Candidate dose level and validation of biochemical markers indicative of HF0220 action. Started Feb 2006; status: completed.
02
Drugs
7-beta-hydroxyepiandrosterone
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2005-005791-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005791-32.